jueves, 8 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Retail banking AI readiness: the leading banks positioned to enable AI at scale

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Retail banking AI readiness: the leading banks positioned to enable AI at scale Date: 2025-12-22 23:05 Source: https://www.cbinsights.com/research/ai-readiness-index-retail-banking-2025/ <p>AI is now a universal focus for retail banks, with <a href="https://www.cbinsights.com/research…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lloyds Banking Group ranks 20th by market capitalization but places 7th overall on the AI Readiness Index

    80% confidence
  • Citigroup is ranked second in the AI Readiness Index and is delivering measurable results from AI initiatives generating tangible internal ROI across coding, wealth management, and customer support

    80% confidence
  • Mistral AI's Mosaic score increased 12% since its partnership with BNP Paribas began

    80% confidence
  • A widening gap exists between AI leaders and followers in retail banking; a small group has built capabilities to scale autonomous AI workflows while others remain active but fragmented

    80% confidence
  • Lloyds Banking Group has eight AI-focused business relationships, keeping pace with top-ranked banks in the index

    80% confidence
  • JPMorgan Chase leads the AI Readiness Index with aggressive efforts across execution and innovation since 2023

    80% confidence
  • Banks that bring agentic AI into production in 2026 will extend their lead, while those still confined to pilots will struggle as autonomous workflows become table stakes

    80% confidence
  • AI readiness among top-tier banks tracks closely with proprietary development as AI systems move closer to autonomy

    80% confidence
  • AI investment in banks, branches, technology will continue regardless of the economic environment

    80% confidence
  • Deep infrastructure partnerships can close agentic readiness gaps fast but only when embedded in core operations, not treated as isolated pilots

    80% confidence
  • Wells Fargo has filed over 100 AI-related patents since 2023

    80% confidence
  • Bank of America has filed more than twice as many AI-related patents since 2023 compared to JPMorgan Chase, despite having less than half its market cap

    80% confidence
  • BNP Paribas's Mistral AI partnership has expanded from Global Markets to multiple business lines powering hundreds of use cases including customer communications analysis, mortgage processing, and ESG assessment

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com